Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519428 · ClinicalTrials.gov registry record · Phase 4
Does Dual Therapy Hasten Antidepressant Response?
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 245
- Enrollment target
NCT00519428 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 245 participants.
The verdict
NCT00519428, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 245 participants
- Enrollment target
Study Summary
This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates than either monotherapy in 240 depressed subjects.
Interventions
- DRUG escitalopram
- DRUG bupropion extra long (XL)
- DRUG escitalopram + bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00519428
The ClinicalTrials.gov registry entry for NCT00519428 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which escitalopram is the first listed.
NCT00519428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00519428 about?
NCT00519428 is a clinical study titled "Does Dual Therapy Hasten Antidepressant Response?". This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates than either monotherapy in 240 depressed subjects.
What is the current status of trial NCT00519428?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 245 participants. The study started on 2007-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00519428?
The interventions under investigation include: escitalopram (DRUG), bupropion extra long (XL) (DRUG), escitalopram + bupropion (DRUG).
Who is sponsoring clinical trial NCT00519428?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.